总结:心脏源性分泌物质(Cardiac Secretome)汇总

2013-04-11 MedSci MedSci原创

    心脏不仅是一个动力器官,亦是一个内分泌组织,它可以产生和释放几百种生物活性物质。主要是多肽和蛋白质,总称为Cardiac Secretome。应用蛋白质组分析在细胞中约含20000多种蛋白质。目前鉴定出的分泌蛋白和多肽约有1000-2000种,约占细胞蛋白总数的 5-10%。在心肌细胞鉴定出的分泌蛋白,现在约有80-120多种,它们或有信号肽序列、或有穿膜Do

    心脏不仅是一个动力器官,亦是一个内分泌组织,它可以产生和释放几百种生物活性物质。主要是多肽和蛋白质,总称为Cardiac Secretome。应用蛋白质组分析在细胞中约含20000多种蛋白质。目前鉴定出的分泌蛋白和多肽约有1000-2000种,约占细胞蛋白总数的 5-10%。在心肌细胞鉴定出的分泌蛋白,现在约有80-120多种,它们或有信号肽序列、或有穿膜Domain,或有KDEL四种氨基酸的Motif 等。但确切的心肌分泌蛋白和多肽数目尚不清楚,目前多是一种估计。心源性分泌物质大体可分为以下三大类: 心源性激素和生长因子:如心钠素、脑钠素、血管紧张素、肾上腺髓质素、Intermedin、降钙素基因相关肽、BK、ET、阿片肽、VEGF、Apelin、Adiponectin、IGF、FGF、TGF-β等等。在体内主要起旁分泌和循环分泌作用。它们是维持和调节心血管功能和肾脏水钠平衡的主要活性物质。 心源性介质:亦称心源性细胞因子(Cardiokines或Cardiomyokines,CK或CMK),如TNF-α、白细胞介素、TGF-β、IL-6、MC

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1913804, encodeId=4207191380485, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Mar 08 06:59:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636641, encodeId=56c11636641f7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 25 13:59:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682140, encodeId=fad41682140d1, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jul 25 13:59:00 CST 2013, time=2013-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041817, encodeId=4dec204181ece, content=<a href='/topic/show?id=9c7531e85c9' target=_blank style='color:#2F92EE;'>#分泌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31785, encryptionId=9c7531e85c9, topicName=分泌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 16 08:59:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426449, encodeId=d1d41426449ce, content=<a href='/topic/show?id=afc96505af' target=_blank style='color:#2F92EE;'>#ECR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6505, encryptionId=afc96505af, topicName=ECR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51824069026, createdName=diushouji, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581445, encodeId=31c815814458e, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
    2014-03-08 ysjykql
  2. [GetPortalCommentsPageByObjectIdResponse(id=1913804, encodeId=4207191380485, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Mar 08 06:59:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636641, encodeId=56c11636641f7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 25 13:59:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682140, encodeId=fad41682140d1, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jul 25 13:59:00 CST 2013, time=2013-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041817, encodeId=4dec204181ece, content=<a href='/topic/show?id=9c7531e85c9' target=_blank style='color:#2F92EE;'>#分泌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31785, encryptionId=9c7531e85c9, topicName=分泌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 16 08:59:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426449, encodeId=d1d41426449ce, content=<a href='/topic/show?id=afc96505af' target=_blank style='color:#2F92EE;'>#ECR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6505, encryptionId=afc96505af, topicName=ECR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51824069026, createdName=diushouji, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581445, encodeId=31c815814458e, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1913804, encodeId=4207191380485, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Mar 08 06:59:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636641, encodeId=56c11636641f7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 25 13:59:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682140, encodeId=fad41682140d1, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jul 25 13:59:00 CST 2013, time=2013-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041817, encodeId=4dec204181ece, content=<a href='/topic/show?id=9c7531e85c9' target=_blank style='color:#2F92EE;'>#分泌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31785, encryptionId=9c7531e85c9, topicName=分泌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 16 08:59:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426449, encodeId=d1d41426449ce, content=<a href='/topic/show?id=afc96505af' target=_blank style='color:#2F92EE;'>#ECR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6505, encryptionId=afc96505af, topicName=ECR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51824069026, createdName=diushouji, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581445, encodeId=31c815814458e, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
    2013-07-25 gwc392
  4. [GetPortalCommentsPageByObjectIdResponse(id=1913804, encodeId=4207191380485, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Mar 08 06:59:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636641, encodeId=56c11636641f7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 25 13:59:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682140, encodeId=fad41682140d1, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jul 25 13:59:00 CST 2013, time=2013-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041817, encodeId=4dec204181ece, content=<a href='/topic/show?id=9c7531e85c9' target=_blank style='color:#2F92EE;'>#分泌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31785, encryptionId=9c7531e85c9, topicName=分泌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 16 08:59:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426449, encodeId=d1d41426449ce, content=<a href='/topic/show?id=afc96505af' target=_blank style='color:#2F92EE;'>#ECR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6505, encryptionId=afc96505af, topicName=ECR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51824069026, createdName=diushouji, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581445, encodeId=31c815814458e, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1913804, encodeId=4207191380485, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Mar 08 06:59:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636641, encodeId=56c11636641f7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 25 13:59:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682140, encodeId=fad41682140d1, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jul 25 13:59:00 CST 2013, time=2013-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041817, encodeId=4dec204181ece, content=<a href='/topic/show?id=9c7531e85c9' target=_blank style='color:#2F92EE;'>#分泌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31785, encryptionId=9c7531e85c9, topicName=分泌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 16 08:59:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426449, encodeId=d1d41426449ce, content=<a href='/topic/show?id=afc96505af' target=_blank style='color:#2F92EE;'>#ECR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6505, encryptionId=afc96505af, topicName=ECR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51824069026, createdName=diushouji, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581445, encodeId=31c815814458e, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
    2013-04-13 diushouji
  6. [GetPortalCommentsPageByObjectIdResponse(id=1913804, encodeId=4207191380485, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Mar 08 06:59:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636641, encodeId=56c11636641f7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 25 13:59:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682140, encodeId=fad41682140d1, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jul 25 13:59:00 CST 2013, time=2013-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041817, encodeId=4dec204181ece, content=<a href='/topic/show?id=9c7531e85c9' target=_blank style='color:#2F92EE;'>#分泌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31785, encryptionId=9c7531e85c9, topicName=分泌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 16 08:59:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426449, encodeId=d1d41426449ce, content=<a href='/topic/show?id=afc96505af' target=_blank style='color:#2F92EE;'>#ECR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6505, encryptionId=afc96505af, topicName=ECR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51824069026, createdName=diushouji, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581445, encodeId=31c815814458e, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Apr 13 13:59:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
    2013-04-13 HinsMax

相关资讯

JBC:DES基因触发心律失常性右心室心肌病

畸形的结蛋白与同种类的完整蛋白质相聚合从而引发骨骼肌和心肌疾病。这项研究由RUB心脏和糖尿病中心完成,领导者为Hendrik Milting博士在与同事Würzburg和 Bielefeld。他们研究报告刊登在Journal of Biological Chemistry杂志上。 一个有缺陷的基因是足以诱发疾病 通常,在细胞内结蛋白形成稳定细丝。DES基因突变后会诱发不同的肌肉疾病。由于染色体

Am Heart J:新诊断房颤患者抗凝药应用存在专科差异

  美国学者的一项研究表明,心脏专科治疗可对新诊断房颤患者的抗凝药物应用产生显著影响,并进而有可能影响临床转归。论文于2012年11月21日在线发表于《美国心脏杂志》(Am Heart J)。   此项研究共纳入141642例新诊断房颤患者。受试者在诊断房颤后90天内至少一次就诊于内科/社区门诊或心脏科门诊。受试者平均年龄为(72.3±10.2)岁,女性占1.48%,并且有2

AHA2012:鱼油并未减少心脏术后AF发生

一项研究显示,心脏手术病人短期使用鱼油未能减少术后心房纤维性颤动(AF)的发生率。意太利RobertoMarchioli博士今日在此于美国心脏协会(AHA)2012年学术会议上提交其最新的临床试验所见结果。他解释说术后AF很常见,累及30%心外科手术后极其衰弱的病人。 在该项命名为“Omega-3脂肪酸用于预防手术后心房纤维性颤动(OPERA)”的研究中,积极治疗组和安慰剂组在预防术后AF上未见

Heart:GGT高水平与偶发心衰相关

  在芬兰人群中的一项研究表明,中、高水平血清γ-谷氨酰转肽酶(GGT)与偶发性心衰显著相关,并且在60岁以下人群中更具预测价值。论文于2012年11月9日在线发表于《心脏》(Heart)杂志。   此项基于人群的前瞻性队列研究共纳入18353例芬兰男性和19726例芬兰女性;受试者年龄为25~74岁,并且基线时均无心衰。主要转归指标为平均随访14.5年间的心衰发生情况。基线时不同水平的血清GG

微创术解除漏斗胸压迫症状

     北京军区总医院刘吉福、刘涛等的一项研究表明,成人漏斗胸前胸壁凹陷畸形对心脏的影响主要是压迫和推移,微创外科治疗可有效解除心脏压迫,消除临床症状。 该论文发表在2012年第9期《中国修复重建外科杂志》。   该研究回顾了2009年8月-2010年12月,采用微创外科矫治102例成人漏斗胸患者。男84例,女18例;平均年龄 23.4岁。初次手术95例,二次手术7例。漏

Nature:美科学家发现心脏修复的新策略

5月13日,Nature在线发表了德克萨斯大学西南医学中心等多家科研单位的一篇题为Heart repair by reprogramming non-myocytes with cardiac transcription factors的文章,研究表明:在体内或体外通过四种心脏转录因子(GATA4,HAND2, MEF2C and TBX5)可以将成年鼠纤维原细胞重编程为功能性的心脏样肌细胞。